BioDelivery Sciences (NSDQ:BDSI) is a specialty pharmaceutical company that last year achieved a 617% growth rate, as shown in Deloitte’s 2020 Technology Fast 500 Rankings. The company is focused on meeting unmet needs of patients with chronic conditions.
We interviewed Scott Plesha, the company’s president and chief commercial officer, to learn more about the company. In the following interview, Plesha touches on chronic pain management’s future and provides an overview of BioDelivery Science’s current product lineup and reflects on the healthcare ecosystem’s return to more-normal operations.
Pharmaceutical Processing World: Can you share some thoughts about the future of chronic pain management and the role that BioDelivery Sciences (BDSI) will play in it?
Plesha: We want the future of chronic pain management to include a greater understanding of chronic pain. That would en…